檢索結果 - Michael Becka

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

    Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects 由 Wolfgang Mueck, Dagmar Kubitza, Michael Becka

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban—An Oral, Direct Factor Xa Inhibitor

    The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban—An Oral, Direct Factor Xa Inhibitor 由 Dagmar Kubitza, Michael Becka, Angelika Roth, Wolfgang Mueck

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

    Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban 由 Wolfgang Mueck, Jan Stampfuss, Dagmar Kubitza, Michael Becka

    出版 2013
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects

    Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects 由 Dagmar Kubitza, Michael Becka, Angelika Roth, Wolfgang Mueck

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen

    Rivaroxaban (BAY 59‐7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen 由 Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Michael Zuehlsdorf

    出版 2006
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct <scp>F</scp>actor <scp>X</scp>a inhibitor

    Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct <scp>F</scp>actor <scp>X</scp>a inhibitor 由 Dagmar Kubitza, Angelika Roth, Michael Becka, Abir Alatrach, Atef Halabi, Holger Hinrichsen, Wolfgang Mueck

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study

    Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study 由 Reinhold Kreutz, Pontus B. Persson, Dagmar Kubitza, Karin Thelen, Stefan Heitmeier, Stephan Schwers, Michael Becka, Melanie Hemmrich

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

    Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor 由 Dagmar Kubitza, Michael Becka, Wolfgang Mueck, Atef Halabi, Haidar Maatouk, Norbert Klause, Volkmar Lufft, Dominic D. Wand, Thomas Philipp, Heike Bruck

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Serum markers detect the presence of liver fibrosis: A cohort study

    Serum markers detect the presence of liver fibrosis: A cohort study 由 William Rosenberg, Michael Voelker, Robert Thiel, Michael Becka, Alastair D. Burt, Detlef Schuppan, Stefan G. Hübscher, Tania Roskams, Massimo Pinzani, Michael J.P. Arthur

    出版 2004
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: